Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
Candel Therapeutics (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies for cancer, announced its upcoming presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting. The event will take place from November 6-10, 2024, in Houston, Texas, and virtually.
The company will present a poster titled 'Therapeutic potential of CAN-3110 in Ras-Raf pathway altered melanoma'. Dr. Anne Diers, Senior Director of Research at Candel Therapeutics, will present the abstract numbered 995 on Friday, November 8, 2024, in the Exhibit Halls A and B of the George R. Brown Convention Center.
Additional details from the presentation will be made available on Candel's website following the event.
Candel Therapeutics (Nasdaq: CADL), una azienda biofarmaceutica in fase clinica che sviluppa immunoterapie biologiche multimodali per il cancro, ha annunciato la sua prossima presentazione al 39° Congresso Annuale della Society for Immunotherapy of Cancer (SITC). L'evento si terrà dal 6 al 10 novembre 2024, a Houston, Texas, e virtualmente.
L'azienda presenterà un poster intitolato 'Potenziale terapeutico di CAN-3110 nel melanoma alterato dalla via Ras-Raf'. La Dott.ssa Anne Diers, Direttore Senior della Ricerca presso Candel Therapeutics, presenterà l'abstract numero 995 venerdì 8 novembre 2024, nelle Sale Espositive A e B del George R. Brown Convention Center.
I dettagli aggiuntivi della presentazione saranno resi disponibili sul sito web di Candel dopo l'evento.
Candel Therapeutics (Nasdaq: CADL), una compañía biofarmacéutica en fase clínica que desarrolla inmunoterapias biológicas multimodales para el cáncer, anunció su próxima presentación en el 39° Congreso Anual de la Society for Immunotherapy of Cancer (SITC). El evento se llevará a cabo del 6 al 10 de noviembre de 2024, en Houston, Texas, y virtualmente.
La compañía presentará un póster titulado 'Potencial terapéutico de CAN-3110 en melanoma alterado por la vía Ras-Raf'. La Dra. Anne Diers, Directora Senior de Investigación en Candel Therapeutics, presentará el resumen número 995 el viernes 8 de noviembre de 2024, en los Salones de Exposición A y B del George R. Brown Convention Center.
Los detalles adicionales de la presentación estarán disponibles en el sitio web de Candel después del evento.
캔델 테라퓨틱스(Candel Therapeutics, 나스닥: CADL)는 암을 위한 다중 생물학적 면역요법을 개발하고 있는 임상 단계의 생물 제약 회사로, 암 면역 치료 학회의 제39회 연례 회의(SITC)에서의 발표를 알렸습니다. 이 행사는 2024년 11월 6일부터 10일까지 텍사스 휴스턴에서 오프라인 및 온라인으로 열립니다.
회사는 'Ras-Raf 경로가 변형된 멜라놈에서의 CAN-3110의 치료 가능성'이라는 제목의 포스터를 발표할 예정입니다. 캔델 테라퓨틱스의 연구 수석 이사인 앤 디어스 박사가 2024년 11월 8일 금요일, 조지 R. 브라운 컨벤션 센터의 A 및 B 전시홀에서 995번 초록을 발표할 것입니다.
발표에 대한 추가 세부 정보는 행사 이후 캔델 웹사이트에 게재될 예정입니다.
Candel Therapeutics (Nasdaq: CADL), une entreprise bio-pharmaceutique en phase clinique développant des immunothérapies biologiques multimodales pour le cancer, a annoncé sa prochaine présentation lors de la 39e Réunion Annuelle de la Society for Immunotherapy of Cancer (SITC). L'événement se déroulera du 6 au 10 novembre 2024, à Houston, Texas, et virtuellement.
L'entreprise présentera un poster intitulé 'Potentiel thérapeutique de CAN-3110 dans le mélanome altéré par la voie Ras-Raf'. Dr. Anne Diers, Directrice de Recherche Senior chez Candel Therapeutics, présentera le résumé numéro 995 le vendredi 8 novembre 2024, dans les Halls d'Exposition A et B du George R. Brown Convention Center.
Des détails supplémentaires sur la présentation seront disponibles sur le site Web de Candel après l'événement.
Candel Therapeutics (Nasdaq: CADL), ein biopharmazeutisches Unternehmen in der Klinikphase, das multimodale biologische Immuntherapien gegen Krebs entwickelt, hat seine bevorstehende Präsentation auf dem 39. Jahreskongress der Society for Immunotherapy of Cancer (SITC) angekündigt. Die Veranstaltung findet vom 6. bis 10. November 2024 in Houston, Texas, sowie virtuell statt.
Das Unternehmen wird ein Plakat mit dem Titel 'Therapeutisches Potenzial von CAN-3110 bei Melanom mit veränderter Ras-Raf-Signalweg' präsentieren. Dr. Anne Diers, Senior Research Director bei Candel Therapeutics, wird am Freitag, den 8. November 2024, das Abstract Nummer 995 in den Ausstellungshallen A und B des George R. Brown Convention Centers präsentieren.
Weitere Details zur Präsentation werden nach der Veranstaltung auf der Website von Candel verfügbar sein.
- Candel Therapeutics will present preclinical data on CAN-3110's potential in melanoma treatment
- The company's research is being showcased at a major cancer immunotherapy conference
- None.
NEEDHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a poster at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting taking place November 6-10, 2024 in Houston, Texas and virtually.
Presentation details are as follows:
Title: Therapeutic potential of CAN-3110 in Ras-Raf pathway altered melanoma
Presenter: Anne Diers, PhD, Senior Director, Research, Candel Therapeutics
Abstract Number: 995
Session Date: Friday, Nov. 8, 2024
Location: Exhibit Halls A and B – George R. Brown Convention Center
Further details from the presentation will be available following the events on the Candel website at: https://www.candeltx.com/media/
About CAN-3110
CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate designed with dual activity for oncolysis and immune activation in a single therapeutic. Its activity is designed to be conditional to the expression of Nestin in cancer cells. CAN-3110 is being evaluated in a phase 1b clinical trial in patients with recurrent high-grade glioma (rHGG). In October 2023, the Company announced that Nature published results from this ongoing clinical trial. CAN-3110 was well tolerated with no dose-limiting toxicity reported. In the clinical trial, the investigators observed improved median overall survival compared to historical controls after a single CAN-3110 injection in this therapy-resistant condition.1 The Company and academic collaborators are currently evaluating the effects of multiple CAN-3110 injections in rHGG, supported by the Break Through Cancer Foundation. CAN-3110 has previously received FDA Fast Track Designation and Orphan Drug Designation for the treatment of rHGG.
About Candel Therapeutics
Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic ductal adenocarcinoma (PDAC) (phase 2), and localized, non-metastatic prostate cancer (phase 2b and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1b clinical trial in recurrent high-grade glioma (rHGG). Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, including key data readout milestones and presentations; expectations regarding early biological readouts as predictor of clinical response; expectations regarding the therapeutic benefit of the Company’s programs, including the ability of CAN-3110 to treat difficult-to-treat cancers; expectations regarding the potential benefits conferred by orphan drug designation and fast track designation; and expectations regarding cash runway and expenditures. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; the Company’s ability to continue as a going concern; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC) including the Company’s most recent Quarterly Report on Form 10-Q filed with the SEC and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Investor Contact:
Theodore Jenkins
VP, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact:
Ben Shannon
Vice President
ICR Westwicke
CandelPR@westwicke.com
1 Ling AL, et al. Nature. 2023;623(7985):157-166.
FAQ
What will Candel Therapeutics (CADL) present at the SITC 2024 Annual Meeting?
When and where is the SITC 2024 Annual Meeting where Candel Therapeutics (CADL) will present?
Who will present Candel Therapeutics' (CADL) research at the SITC 2024 Annual Meeting?
What is the focus of Candel Therapeutics' (CADL) presentation at SITC 2024?
